Tenaya治疗公司是一家心脏病公司,其潜在收益高于以癌症为重点的PharmaCyte生物科技。 Tenaya Therapeutics, a heart disease firm, shows higher potential gains than cancer-focused PharmaCyte Biotech.

Tenaya治疗技术公司是一家发展心脏病治疗的生物技术公司,在六个关键因素方面表现优于PharmaCyte生物技术,其中包括更高的潜力和更强的分析师评级。 Tenaya Therapeutics, a biotech firm developing heart disease treatments, outperforms PharmaCyte Biotech on six key factors including higher potential upside and stronger analyst ratings. PharmaCyte生物技术关注的癌症和糖尿病的波动性较小,但Tenaya治疗技术的目标价格较高,表明潜在收益为1 447.62%,尽管股票波动性更大,但更有利。 PharmaCyte Biotech focuses on cancer and diabetes with less volatility, but Tenaya Therapeutics has a higher target price, indicating a potential 1,447.62% gain, making it more favorable despite greater stock volatility.